Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in COPD
Information source: Boehringer Ingelheim Pharmaceuticals
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pulmonary Disease, Chronic Obstructive
Intervention: Tiotropium (Drug); Salmeterol plus Fluticasone (Drug)
Phase: Phase 4
Sponsored by: Boehringer Ingelheim Pharmaceuticals
Official(s) and/or principal investigator(s):
Boehringer Ingelheim Study Coordinator, Study Chair, Affiliation: B.I. South Africa (Pty.) Ltd.
The primary objective of this study is to estimate the comparative bronchodilator effect size
and variability for tiotropium (Spiriva, 18 µg q. d.) with the free combination of salmeterol
(Serevent, 50 µg b. i.d.) and fluticasone (Flixotide, 250 µg b. i.d.) in COPD patients.
International COPD guidelines preserve milder stages of the disease (GOLD stage I and IIa) to
bronchodilators and recommend the addition of inhaled corticosteroids only in those patients
who have a documented spirometric response to inhaled corticosteroids and in patients with a
postbronchodilator FEV1 of less than 50% predicted, who suffer from frequent exacerbations
requiring oral courses of corticosteroids.
Recently published reports indicate that additional bronchodilator efficacy may be achieved
when a long-acting beta agonist is combined with an inhaled corticosteroid. Steady state
bronchodilation was achieved within one week with the drug combination. However, results of
these studies are not consistent, and since the inclusion criteria employed were different
from those utilised in the previously conducted tiotropium studies, it is difficult to
generalise the observed effects to the general COPD population.
In addition, no comparative data is available on the average response over the 12 daytime
hours when COPD patients are active and in most need of bronchodilation. 12 hours
corresponds to the dosing intervals for both salmeterol and fluticasone.
Official title: A Multiple Dose Pilot Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol Combined With Fluticasone Inhalation Aerosol in a Six-Week, Randomized, Double-Blind, Triple-Dummy Parallel Group Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Primary outcome: The primary efficacy endpoint will be FEV1 area under the curve for the time period 0 to 12 hours (FEV1 AUC0-12) measured after 6 weeks of treatment, at the final study visit (Visit 4).
Secondary outcome: Trough and peak FEV1.
Trough FVC at Visits 3 and 4 and peak FVC and FVC AUC0-12 at Visit 4.
Individual FEV1 and FVC measurements at each time point.
Weekly mean number of puffs of rescue therapy used per day and night .
This is a six-week, multi-centre, randomised, double-blind, triple-dummy, parallel group
pilot study to compare the bronchodilator efficacy and safety of the long-acting
bronchodilator tiotropium (Spiriva, 18 Âµg q. d.) to the free combination of fluticasone
(Flixotide, 250 Âµg b. i.d.) and salmeterol (Serevent, 50 Âµg b. i.d.) in patients with COPD.
Following an initial screening at Visit 1, subjects will enter a two-week run-in period
during which they will record daily rescue salbutamol use in the Patient Daily Diary Card.
At Visit 1, pre-dose and post-bronchodilator pulmonary function tests (PFT) will be measured.
Four inhalations of ipratropium (20 Âµg per puff) and four inhalations of salbutamol (100 Âµg
per puff) will be administered 60 minutes prior to obtaining post-bronchodilator PFT
At Visit 2, a pre-dose PFT will be performed prior to first administration of trial
medication. Treatment with blinded study medication (tiotropium or fluticasone + salmeterol)
will start in the morning of Visit 2 (Day 1). After three weeks of treatment, at Visit 3
(Day 22), pre-dose FEV1 and FVC will be measured, patient compliance checked and a re-supply
of study medication dispensed. After six weeks of treatment, at Visit 4 (Day 43), a 12 hour
profile of PFTs will be obtained.
As this is a pilot trial to investigate the efficacy and safety of tiotropium (18 Âµg q. d.) as
compared to the free combination of fluticasone (250 Âµg b. i.d.) and salmeterol (50 Âµg
b. i.d.), no formal hypothesis testing will be performed. However, the underlying hypothesis
for this trial is that tiotropium is superior to the free combination with respect to the
primary efficacy endpoint FEV1AUC0-12 (area under the curve for the time period 0 to 12
At least 100 male or female outpatients with clinical and spirometric evidence of chronic
obstructive pulmonary disease (COPD) will be entered in this study. Patients will be
randomly assigned to receive either tiotropium inhalation capsules 18 Âµg q. d., or salmeterol
50 Âµg oral inhalation b. i.d. in free combination with fluticasone 250 Âµg oral inhalation
b. i.d. in a double-blind triple-dummy fashion.
Minimum age: 40 Years.
Maximum age: N/A.
- All patients must have a diagnosis of chronic obstructive pulmonary disease according
to the GOLD criteria and must meet the following spirometric criteria:
- Patients must have relatively stable airway obstruction with a
post-bronchodilator FEV1 < 80% of predicted normal and FEV1/FVC < 70% at Visit 1,
and a pre-dose FEV1 < 65% predicted at Visit 2.
- Male or female patients 40 years of age or older. There is no upper age limit.
- Patients must be current or ex-smokers with a smoking history of more than 10
- Patients with significant diseases other than COPD.
- Patients with a history of asthma, allergic rhinitis or atopy or who have a total
blood eosinophil count more than or equal to 600/mm3.
- Patients who have been treated with commercially available tiotropium (SpirivaÂ®).
Locations and Contacts
Boehringer Ingelheim Investigational Site, Pretoria 0001, South Africa
QdotPharma, George 6529, South Africa
Durban Lung Centre, Durban 4001, South Africa
Tijger Trial Centre, Bellville 7530, South Africa
Boehringer Ingelheim Investigational Site, Paarl 7646, South Africa
Vergelegen Medi-Clinic, Somerset West 7130, South Africa
Boehringer Ingelheim Investigational Site, Cape Town 8001, South Africa
Boehringer Ingelheim Investigational Site, Bloemfontein 9301, South Africa
Boehringer Ingelheim Investigational Site, Welkom 9460, South Africa
Centre for Chest Diseases Research Unit, Johannesburg 2193, South Africa
UCT Lung Institute, Cape Town 7700, South Africa
St Augustine Hospital, Durban 4001, South Africa
Starting date: September 2003
Ending date: August 2004
Last updated: April 3, 2008